SCHEDULE


To view our programme, please use the following link:

DOWNLOAD PROGRAMME

Sessions:

1. Pathogenesis of PD and MSA and relevance of preclinical models for treatment development

2. Biomarkers: diagnosis, prognosis and outcomes for clinical trials

3. Clinical challenges and clinical trials in PD and MSA

SPEAKERS


Omar El-Agnaf

Hamid Bin Khalifa University
Qatar

Omar El-Agnaf was awarded a PhD in Biochemistry in 1997 at the Queen’s University Belfast, UK, where he continued his post-doctoral training. In 2001 he established his own research group at Lancaster University. He is currently Professor of Life Sciences at Hamad Bin Khalifa University and acting Executive Director of Qatar Biomedical Research Institute (QBRI). His research focuses on neurodegenerative diseases, specifically Parkinson’s disease.
Photo: © Omar El-Agnaf

Kuldip Dave

Michael J. Fox Foundation
USA

Kuldip Dave earned an undergraduate degree in biology from Rutgers University and a PhD in Pharmacology & Physiology from the MCP-Hahnemann University where his thesis work focused on serotonergic regulation of motor function and learning and memory. He is currently Director of Research Programs at the Michael J. Fox Foundation, maintaining close links to the Parkinson’s community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson’s disease.
Photo: © Kuldip Dave

Joaquim Ferreira

University of Lisbon
Portugal

Joaquim Ferreira completed his medical degree and PhD in Neurology at the University of Lisbon. He is Professor of Neurology and Clinical Pharmacology at the Faculty of Medicine, University of Lisbon and Head of the Laboratory of Clinical Pharmacology and Therapeutics. He is also the head of CNS – Campus Neurológico Sénior in Portugal.
He became interested in movement disorders during his medical degree and later undertook a Clinical Pharmacology fellowship with Prof. Olivier Rascol in Toulouse, France.
He is currently the chair of the European Section of the International Parkinson and Movement Disorder Society. His major research interests are neuropharmacology, Parkinson’s disease, dystonia and Huntington’s disease.

Gergana Galabova

AFFIRIS AG
Austria

Gergana Galabova completed her veterinary medical studies in 2000 in Bulgaria before moving to Austria for her doctoral and post-doctoral training. In 2009, Gergana left academia to join the biotech company AFFiRiS AG where she is now head of the Neurodegeneration Department. Her team focus on the preclinical research and development of immunotherapy for the treatment of Parkinson’s disease and Alzheimer’s disease.
Photo: © AFFiRiS / Petra Spiola

Kenneth Marek

Institute for Neurodegenerative Disorders
USA

Kenneth Marek is President and Senior Scientist at the Institute for Neurodegenerative Disorders. His major research interests include the identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson’s disease and Alzheimer’s disease and related neurodegenerative disorders.

Eliezer Masliah

UC San Diego
USA

Eliezer Masliah received his Medical Doctor Degree from the National Autonomous University of Mexico in 1982. He subsequently completed post-graduate residency training at the National Institutes of Health in Mexico City and a fellowship at the University of California, San Diego, where he served as Tenured Professor, Director of the Laboratory of Experimental Neuropathology and Director of the Autopsy Service at the UCSD-Medical Center until the summer 2016. He is currently the Director of the Neurosciences Division at the National Institute on Aging at NIH.
© Photo: Eliezer Masliah

Wassilios Meissner

University Hospital Bordeaux
France

Wassilios Meissner is Professor of Neurology at the University Bordeaux 2 and the University Hospital Bordeaux. He has since 2012 served as co-chair of the French National Reference Centre for multiple-system atrophy. His current research interests focus on multiple-system atrophy pathophysiology (preclinical and clinical), biological and clinical markers of disease progression and treatment.
Photo: © Markus Schieder – CREVO Creative Volume e.U.

Werner Poewe

Medical University Innsbruck
Austria

Werner Poewe is Professor of Neurology and Director of the Department of Neurology at the Medical University of Innsbruck, Austria. His main clinical and research interests lie within movement disorders: clinical studies in Parkinson’s disease and movement disorders; imaging of movement disorders; multiple-system atrophy atypical Parkinsonism; movement disorders and sleep.
Photo: © Markus Schieder – CREVO Creative Volume e.U.

Dieter Volc

Prosenex Ambulatorium BetriebsgesmbH
Austria

Dieter Volc is a specialist in neurology and psychiatry and head of the Neurology Department & Movement Disorders Center at Confraternitaet-Privatklinik Josefstadt. He is the founder of PROSENEX AmbulatoriumbetriebsgesmbH, a private outpatient facility for neurogeriatric disorders. Dieter Volc has been involved in various clinical trials and programs in neurogeriatrics, especially with Parkinson’s and Alzheimer´s disease.
Photo: © Markus Schieder – CREVO Creative Volume e.U.

Dieter Willbold

Forschungszentrum Jülich GmbH
Germany

Dieter Willbold completed his doctoral training in biochemistry at the Universities of Tübingen, Bayreuth and Boulder (CO, USA). He is now director of the Institute of Complex Systems (ICS-6), Forschungszentrum Jülich and also Professor for Physical Biology at the Heinrich-Heine-University Düsseldorf (HHUD). His expertise is in structural biology, NMR spectroscopy and protein-ligand interactions.
Photo: © Markus Schieder – CREVO Creative Volume e.U.